Successful switch from clozapine to aripiprazole: A case report

Journal of Clinical Psychopharmacology

Volumn 29, Issue 1, 2009, Pages 93-95

  Jong Yih, Lin ^a  

^a TAINAN MUNICIPAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; BEDTIME DOSAGE; CASE REPORT; DELUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HYPERSALIVATION; LETTER; MALE; MONOTHERAPY; PARANOIA; PRIORITY JOURNAL; SCHIZOPHRENIA; SOMNOLENCE; DRUG ADMINISTRATION; DRUG RESISTANCE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; HUMANS; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 62649129812     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318193c765     Document Type: Letter

References (12)

1. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry. 1999;60(suppl 23):14-19.
2. Meltzer HY, Lee MA, Ranjan R, et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology (Berl). 1996;124:176-187.
3. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156:876-884.
4. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of psychotic monotherapy. J Clin Psychiatry. 1996;57(suppl 9):5-9.
5. Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol. 2001;21(4):398-407.
6. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007;22(5):358-366.
7. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715-1736.
8. 2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther. 2002;301:1166-1178.
9. Parsa MA, Al-Lahham YH, Ramirez LF, et al. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol. 1993;13:154-155.
10. Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213-223.
11. Casey DE, Carson WH, Saha AR. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology. 2003;166:391-399.
12. Fan CT, Lin JC, Lee CH. Taiwan Biobank: a project aiming to aid Taiwan's transition into a biomedical island. Pharmacogenomics. 2008;9(2):235-246.